Bronchiolitis Obliterans Syndrome Market Size
Market Size in USD Mn
CAGR4.3%
| Study Period | 2025-2032 |
| Base Year of Estimation | 2024 |
| CAGR | 4.3% |
| Market Concentration | Medium |
| Major Players | Zambon Pharma, Incyte Corporation, Genentech, GlaxoSmithKline, Altavant Sciences and Among Others |
*Disclaimer: Major players are listed in no particular order.
*Source: Coherent Market Insights
Want to purchase customized report?
please let us know !
please let us know !
Bronchiolitis Obliterans Syndrome Market Analysis
The bronchiolitis obliterans syndrome market is estimated to be valued at USD 63.0 Mn in 2025 and is expected to reach USD 84.6 Mn by 2032, growing at a compound annual growth rate (CAGR) of 4.3% from 2025 to 2032. The prevalence of bronchiolitis obliterans syndrome (BOS) is increasing which is driving the demand for effective therapeutics. With no approved drug therapy currently available for BOS, the pipeline drugs in late-stage clinical trials holds significant potential to capture market share if approved.